Topical composition comprised of cod liver oil for treating wounds and skin disorders
Inventors
Bettle, III, Griscom • Harlin, John • Gardner, Thomas
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12186347-B2
Publication Date
2025-01-07
Expiration Date
Abstract
Disclosed is a topical anhydrous, homogenous pharmaceutical composition for treating skin disorder and wounds comprising cod liver oil, hempseed oil, monolaurin, medium chain triglycerides (“MCT”), free fatty acids, sea salt, and vegetable oil selected from the group consisting of red palm concentrate, coconut oil, and red palm oil and combination thereof and optionally fish collagen, ascorbyl palmitate, thickening agent, such as beeswax, red palm concentrate and cetyl ester.
Core Innovation
The invention provides an anhydrous topical composition comprising an omega fatty acid product and a nonoxidizing semi-occlusive film. The omega fatty acid product comprises cod liver oil, hempseed oil, an analgesic, and C8 free fatty acid (FFA), where the cod liver oil, the hempseed oil, or both comprise a weight ratio of omega-6 fatty acid to omega-3 fatty acid of at least 1.0 to at most 3.0. In some embodiments the composition is homogeneous and single-phase, and the omega fatty acid product includes about 5% to about 30% cod liver oil by weight, about 5% to about 30% hempseed oil by weight, about 0.5% to about 1.5% analgesic by weight, and 0.3% to 1.6% C8 FFA by weight.
After being disposed about at least one portion of a skin condition, a surrounding periwound, or both, protonation of the C8 FFA causes inhibition of bacterial cell growth. The nonoxidizing semi-occlusive film participates in the condition of use and is associated with the claimed inhibition outcome. The composition is described as an oil-containing topical wound/skin pharmaceutical composition intended to act in relation to the skin condition and periwound.
The disclosed formulation includes product distinctions and additional component options, including collagen-containing versus collagen-free products, cetyl esters and beeswax in a wax system associated with the semi-occlusive film, and an odorless omega fatty acid product. The composition is described as maintaining monophasic stability without oil seepage during storage and vial filling, while also being processable due to a wax system having multiple eutectic melting points.
Claims Coverage
The document identifies a single core composition claim with specified omega fatty acid product ranges, a constrained omega-6 to omega-3 ratio, and a nonoxidizing semi-occlusive film, together with a functional bacterial-growth inhibition mechanism. Dependent claim refinements further specify additional ingredients and formulation/property constraints.
Anhydrous topical omega fatty acid composition with cod liver oil, hempseed oil, analgesic, and C8 FFA
An anhydrous topical composition comprising an omega fatty acid product comprising cod liver oil, hempseed oil, an analgesic, and C8 free fatty acid (FFA), including about 5% to about 30% cod liver oil by weight, about 5% to about 30% hempseed oil by weight, about 0.5% to about 1.5% analgesic by weight, and 0.3% to 1.6% C8 FFA by weight.
Omega-6 to omega-3 ratio constraint in cod liver oil and/or hempseed oil
The cod liver oil, the hempseed oil, or both comprise a weight ratio of omega-6 fatty acid to omega-3 fatty acid of at least 1.0 to at most 3.0.
Nonoxidizing semi-occlusive film with C8 FFA protonation inhibition
The omega fatty acid product further comprises a nonoxidizing semi-occlusive film, wherein after being disposed about at least one portion of a skin condition, a surrounding periwound, or both, protonation of the C8 FFA causes inhibition of bacterial cell growth.
Cetyl esters-containing nonoxidizing semi-occlusive film
The nonoxidizing semi-occlusive film includes cetyl esters.
Odorless omega fatty acid product
The omega fatty acid product has no odor.
Medium chain triglycerides content range in the omega fatty acid product
The omega fatty acid product includes about 20% to about 50% medium chain triglycerides (MCT) by weight.
Specific MCT-to-oil weight ratio
The omega fatty acid product has a weight ratio of the MCT to cod liver oil, hempseed oil, or both of 0.66.
Analgesic is lidocaine
The analgesic ingredient is lidocaine.
The claim coverage centers on an anhydrous topical composition with a defined omega fatty acid product, a constrained omega-6 to omega-3 ratio, and a nonoxidizing semi-occlusive film configured such that protonation of the C8 FFA inhibits bacterial cell growth after application. Dependent features further specify cetyl esters, odorless product, MCT content and ratio, and lidocaine as the analgesic.
Stated Advantages
Reduced/eliminated rancid fish odor.
Maintained monophasic stability without oil seepage during storage and vial filling.
Improved manufacturability/dispensing using a wax system with multiple eutectic melting points.
Inhibition of bacterial cell growth after being disposed about at least one portion of a skin condition, a surrounding periwound, or both.
Antimicrobial activity against S. aureus biofilm in an ex vivo porcine wound model for a lidocaine-containing example.
Oil weeping/seepage stability.
Antibacterial/biofilm reduction observations.
Documented Applications
Topical use for a skin condition and/or a surrounding periwound.
Ex vivo porcine wound model testing for S. aureus biofilm (lidocaine-containing example).
Wound-bed context associated with the wax/semi-occlusive film softening near 37°C.
Burn/skin use cases are mentioned as example-driven observations.
Wound bed/skin outcome observations in connection with lidocaine-containing and non-lidocaine variants (scrapes, burns, poison ivy, shingles, ulcers).
Antibacterial/biofilm reduction observations associated with S. aureus.
Ex vivo porcine skin wound model observations.
Interested in licensing this patent?